Form 4: Hims & Hers CFO Executes Planned Stock Sale

Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, exercised stock options and subsequently sold a portion of Class A Common Stock under a pre-arranged trading plan.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on September 29, 2025.
• Okupe exercised stock options to acquire 49,832 shares of Class A Common Stock at an exercise price of $5.01 per share.
• Concurrently, Okupe sold 85,000 shares of Class A Common Stock at a weighted average price of $60.1991 per share, with prices ranging from $59.95 to $60.48.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Following these transactions, Okupe directly beneficially owns 70,232 shares of Class A Common Stock and indirectly owns 7,853 shares through the Oluyemi Okupe Separate Property Trust dtd 9-1-2021.
• Okupe also holds 189,952 derivative securities (stock options) after the reported exercise.
• The options' vesting schedule includes 25% vesting on the 12-month anniversary of January 24, 2022, with the balance vesting in 36 equal monthly installments thereafter, subject to continuous service.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-scheduled insider sale under a 10b5-1 plan, which mitigates the negative sentiment typically associated with insider selling. The significant profit realized from the option exercise reflects positively on the stock's past performance.

Positives

• The Chief Financial Officer realized a significant profit by exercising options at $5.01 and selling shares at an average of $60.1991, indicating strong past performance of the company's stock.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• The sale of 85,000 shares by a key executive, even under a 10b5-1 plan, could be perceived negatively by some investors as a reduction in insider ownership.

Risks

• Insider selling, even when pre-planned, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects.

Stakeholder Impact

• Shareholders may observe the reduction in direct insider ownership, though the pre-planned nature of the sale under Rule 10b5-1 typically lessens concerns about management's confidence in the company's future.

Key Dates

Keywords

Hims & Hers Health, HIMS, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, CFO, Rule 10b5-1 Plan, Beneficial Ownership